Cruz DG, García PDC

Language: Spanish
References: 17
Page: 56-63
PDF size: 249.77 Kb.

ABSTRACT

The gene therapy with viral vectors has gained great importance in recent years. This method has been used in various pathologies, from central nervous system diseases, to congenital diseases. On the other hand, heart diseases have been historically chronic diseases, because patients never lose the risk of complications after having any pathology involving this organ. This article will describe the development of new strategies for the use of viral vectors in heart diseases from 15 literature sources. Some of the vectors that are used today are the Adenovirus serotype 9 (AAV9), serotype 2 (AAV2), serotype 2/5 (AAV2 / 5), serotype 2.6 (AAV2.6), serotype 2.9 (AAV2.9), among others that have already shown good penetration in cardiomyocytes. Although useful, the field remains open to improvement and implementation of new knowledge for this method to be fully exploited.

REFERENCES

1. INEGI. Defunciones registradas por principales causas de mortalidad según sexo. Mujeres y hombres en México 2013. Available from: http://www.inegi.org.mx/

2. CONAPRA. 10 causas de muerte en México. Causas de defunción en México. Available from: http://conapra.salud.gob.mx

3. Cruz G, García D. Papel de los virus en las enfermedades neurodegenerativas: uso beneficioso de vectores virales como terapia e infecciones virales que podrían desencadenar en estas enfermedades. 16 de Abril. 2014;53(256):70-78. Available from: http://www.imbiomed.com.mx/1/1/articulos.php?id_revista=360&id_ejemplar=10152

4. Meloni M, Descamps B, Caporali A, Zentilin L, Floris I, Giacca M, et al. Nerve Growth Factor Gene Therapy Using Adeno-Associated Viral Vectors Prevents Cardiomyopathy in Type 1 Diabetic Mice. Diabetes. 2012; 61(1):229-40.

5. Xie Y, Li M, Wang X, Zhang X, Peng T, Yang Y, et al. In Vivo Delivery of Adenoviral Vector Containing Interleukin-17 Receptor A Reduces Cardiac Remodeling and Improves Myocardial Function in Viral Myocarditis Leading to Dilated Cardiomyopathy. PLoSOne. 2013; 8(8).

6. Wei Q, Huang X, Lin J, Fei Y, Liu Z, Zhang XA. Adeno-associated viral vector-delivered and hypoxia response element-regulated CD151 expression in ischemicratheart. Acta Pharmacol Sin. 2011;32(2):201-8.

7. Fechner H, Sipo I, Westermann D, Pinkert S, Wang X, Suckau L, et al. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. Journal of Molecular Medicine. 2008;86(9):987-97.

8. Williams ML, Koch WJ. Viral based myocardial gene therapy approaches to alter cardiac function. Annu Rev Physiol. 2004;66:49-75.

9. Bouchard S, MacKenzie TC, Radu AP, Hayashi S, Peranteau WH, Chirmule N, et al. Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice. J Gene Med. 2003;5(11):941-50.

10. Raake PW, Hinkel R, Müller S, Delker S, Kreuzpointner R, Kupatt C, et al. Cardio-specific longterm gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther. 2008;15(1):12-7.

11. Ladage D, Ishikawa K, Tilemann L, Müller-ehmsen J, Kawase Y. Percutaneous methods of vector delivery in preclinical models. Gene Ther. 2012;19(6):637-41.

12. Agudelo C, Martínez L. Terapia génica: una opción de tratamiento y una controversia ética. (Spanish). Salud Uninorte [serial on the Internet]. (2013, May), [cited September 9, 2015]; 29(2): 341-350.

13. Mena M, Flores L, Armendáriz J. Adeno-associated viral vectors: methods for production and purification for gene therapy applications. Revista De Investigación Clínica; Órgano del Hospital de Enfermedades de la Nutrición [serial on the Internet]. (2012, Sep), [cited September 9, 2015];64(5):487-94.

14. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 2008;12(23):1550-7.

15. Yu C, Yuan Z, Cao Z, Wang B, Qiao C, Li J, et al. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther. 2009; 16(8):953-62.

16. Zeng J, Chen XX, Dai JP, Zhao XF, Xin G, Su Y, et al. An Attenuated Coxsackievirus B3 Vector: A Potential Tool for Viral Tracking Study and Gene Delivery. PLoS One. 2013;8(12).

17. Henke A, Jarasch N, Wutzler P. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Expert Review of Vaccines. 2008;7(10):1557-67.